With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108149-63-9,(R)-tert-Butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate,as a common compound, the synthetic route is as follows.
a) (R)-2,2-Dimethyl-4-phenoxymethyl-oxazolidine-3-carboxylic acid tert-butyl ester To a stirred solution of tert-butyl (R)-4-(hydroxymethyl)-2,2-dimethyl-3- oxazolidinecarboxylate (400 mg; CAS 108149-63-9) in THF (20 ml) were added phenol (197 mg), triphenylphosphine (573 mg) and di-tert-butyl azodicarboxylate (488 mg). The resulting yellow solution was stirred at 70 0C for 18 h overnight, then concentrated in vacuo. The crude product was purified by column chromatography (SiO2; gradient: heptane/EtOAc 100:0 -> 70:30) to give (R)-2,2-dimethyl-4-phenoxymethyl-oxazolidine- 3-carboxylic acid tert-butyl ester (336 mg, 63%) as a colourless viscous oil. MS (ISP): 308.3 ([M+H]+))., 108149-63-9
The synthetic route of 108149-63-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; WO2008/92785; (2008); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem